Drug Trial Radar · NCT06824467
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
770
Planned (sponsor's estimate)
Start
Apr 9, 2025
Primary completion
Apr 27, 2029
Study completion Nov 9, 2032
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- European Network of Gynaecological Oncological Trial Groups (ENGOT); GOG Foundation
- First posted
- Feb 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.
Conditions
- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
Interventions
Sacituzumab tirumotecanBiological
IV Infusion
BevacizumabBiological
IV Infusion
H1 receptor antagonistDrug
Rescue medication taken per approved product label before sacituzumab tirumotecan
H2 receptor antagonistDrug
Rescue medication taken per approved product label before sacituzumab tirumotecan
Acetaminophen (or equivalent)Drug
Rescue medication taken per approved product label before sacituzumab tirumotecan
Dexamethasone (or equivalent)Drug
Rescue medication taken per approved product label before sacituzumab tirumotecan
Steroid mouthwash (dexamethasone or equivalent)Drug
Rescue medication taken orally 2-4 times daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants With One or More Adverse Events (AEs)Time frame: Up to 6 weeks
- Part 1: Number of Participants Who Discontinue Study Intervention Due to an AETime frame: Up to 6 weeks
- Part 2: Progression-Free Survival (PFS)Time frame: Up to approximately 4 years
Locations
203 sites in 29 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham ( Site 0006)
Birmingham, Alabama · Recruiting
Alaska Women's Cancer Care ( Site 0096)
Anchorage, Alaska · Recruiting
City of Hope Comprehensive Cancer Center ( Site 0007)
Duarte, California · Recruiting
City of Hope Lennar Foundation Cancer Center ( Site 0024)
Irvine, California · Recruiting
Hoag Memorial Hospital Presbyterian ( Site 0019)
Newport Beach, California · Recruiting
UCSF Medical Center at Mission Bay ( Site 0013)
San Francisco, California · Recruiting
John Muir Health Cancer Center ( Site 0016)
Walnut Creek, California · Recruiting
Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0001)
New Haven, Connecticut · Recruiting
Mount Sinai Braman Comprehensive Cancer Center ( Site 0078)
Miami Beach, Florida · Recruiting
Sarasota Memorial Hospital ( Site 0075)
Sarasota, Florida · Recruiting
Florida Cancer Specialists East ( Site 7000)
West Palm Beach, Florida · Recruiting
Winship Cancer Institute of Emory University ( Site 0086)
Atlanta, Georgia · Recruiting
Augusta University - Georgia Cancer Center ( Site 0066)
Augusta, Georgia · Recruiting
Parkview Research Center at Parkview Regional Medical Center ( Site 0003)
Fort Wayne, Indiana · Recruiting
The University of Kansas Cancer Center - Westwood ( Site 0002)
Westwood, Kansas · Recruiting
Women's Cancer Care ( Site 0067)
Covington, Louisiana · Recruiting
Maine Medical Center Research Institute-MaineHealth/Maine Medical Partners - GynOnc ( Site 0008)
Scarborough, Maine · Recruiting
Minnesota Oncology Hematology (MNO) ( Site 8002)
Maplewood, Minnesota · Recruiting
St. Dominic's Hospital ( Site 0064)
Jackson, Mississippi · Active not recruiting
Washington University School of Medicine ( Site 0052)
St Louis, Missouri · Recruiting
Nebraska Methodist Hospital ( Site 0053)
Omaha, Nebraska · Recruiting
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0081)
Hackensack, New Jersey · Recruiting
Rutgers Cancer Institute of New Jersey ( Site 0071)
New Brunswick, New Jersey · Recruiting
University of New Mexico Comprehensive Cancer Center ( Site 0055)
Albuquerque, New Mexico · Recruiting
NYU Langone Hospital - Long Island ( Site 0015)
Mineola, New York · Recruiting
Laura and Isaac Perlmutter Cancer Center ( Site 0076)
New York, New York · Recruiting
FirstHealth Cancer Center ( Site 0079)
Pinehurst, North Carolina · Recruiting
University of Cincinnati Medical Center ( Site 0090)
Cincinnati, Ohio · Recruiting
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0054)
Columbus, Ohio · Recruiting
Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0056)
Tulsa, Oklahoma · Recruiting
Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8010)
Eugene, Oregon · Recruiting
Allegheny Health Network West Penn Hospital ( Site 0099)
Pittsburgh, Pennsylvania · Recruiting
Women & Infants Hospital ( Site 0050)
Providence, Rhode Island · Recruiting
Henry-Joyce Cancer Clinic ( Site 0060)
Nashville, Tennessee · Recruiting
Texas Oncology - Central/South Texas ( Site 8009)
Austin, Texas · Recruiting
Texas Oncology - DFW ( Site 8001)
Fort Worth, Texas · Recruiting
University Of Texas Health Science Center -San Antonio ( Site 0095)
San Antonio, Texas · Recruiting
Texas Oncology - San Antonio ( Site 8005)
San Antonio, Texas · Recruiting
Texas Oncology - Gulf Coast ( Site 8003)
Webster, Texas · Recruiting
Virginia Cancer Specialists (VCS) ( Site 8011)
Fairfax, Virginia · Recruiting
Showing 40 of 203 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.